文献速递妇科

IVB期子宫内膜癌新辅助化疗的人群层面使用趋势

Population-level uptake of neoadjuvant chemotherapy for stage IVB endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2022-04-19

基于美国监测、流行病学和最终结果计划(SEER)2010至2018年5505例IVB期子宫内膜癌患者的回顾性分析,手术前新辅助化疗(NACT)使用比例从11.6%升至21.7%,原发手术后续化疗比例从62.7%降至48.3%(P<0.001)。多变量分析中,NACT后手术与原发手术后化疗的总生存(OS)相当(中位25个月 vs 26个月,调整HR 1.03,95%CI 0.93-1.15)。

要点

  • 2010至2018年IVB期子宫内膜癌中,术前NACT使用比例从11.6%升至21.7%(P<0.001)。
  • 多变量分析中NACT使用增加趋势独立(每年调整OR 1.11,95%CI 1.08-1.15)。
  • NACT后手术与原发手术后化疗的OS相当(中位25 vs 26个月,调整HR 1.03,95%CI 0.93-1.15)。

核心结论

  • 美国IVB期子宫内膜癌的治疗正从原发手术转向NACT。

研究设计与样本

  • 回顾性查询美国国家癌症研究所监测、流行病学和最终结果计划(SEER),分析2010至2018年5505例IVB期子宫内膜癌患者。
  • 按治疗分配:原发手术后化疗3052例(55.4%)、NACT后手术930例(16.9%)、单纯化疗1523例(27.7%)。
  • 主要结局为NACT使用趋势及与NACT相关的患者特征(多项回归分析)和总生存(OS,多变量Cox比例风险回归模型)。

主要发现

  • 接受术前NACT的患者比例从11.6%升至21.7%,原发手术后化疗比例从62.7%降至48.3%(P<0.001)。
  • 多变量分析中NACT使用增加趋势独立(每年调整OR 1.11,95%CI 1.08-1.15)。
  • 多个亚组中观察到NACT使用增加,包括年龄<65岁、≥65岁、白人、非白人、子宫内膜样、非子宫内膜样及非远处器官转移病例(P<0.05)。
  • 多变量分析中,NACT后手术与原发手术后化疗的OS相当(中位25个月 vs 26个月,调整HR 1.03,95%CI 0.93-1.15)。
  • 按转移范围分析,非远处器官转移组中NACT后手术与原发手术后化疗相比OS降低(调整HR 1.20,95%CI 1.05-1.36),而远处器官转移组中OS改善(调整HR 0.79,95%CI 0.66-0.95)。

临床怎么用

  • 原文结论指出美国IVB期子宫内膜癌的治疗正从原发手术转向NACT。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine population-level trends, characteristics, and outcomes of patients with stage IVB endometrial cancer who received neoadjuvant chemotherapy (NACT) prior to surgery. METHODS: The National Cancer Institute's Surveillance, Epidemiology, and End Results Program was retrospectively queried by examining 5505 patients with stage IVB endometrial cancer from 2010 to 2018. Exposure allocation was per treatment: primary surgery followed by chemotherapy (n = 3052, 55.4%), NACT followed by surgery (n = 930, 16.9%), and chemotherapy alone (n = 1523, 27.7%). Main outcomes measured were (i) the trend of utilization of NACT and patient characteristics related to NACT assessed with multinomial regression analysis and (ii) overall survival (OS) assessed with multivariable Cox proportional hazards regression model. RESULTS: The number of patients receiving NACT prior to surgery increased from 11.6% to 21.7% whereas those undergoing primary surgery followed by chemotherapy decreased from 62.7% to 48.3% (P < 0.001). Increasing utilization of NACT remained independent in multivariable analysis (adjusted-odds ratio per one-year increments 1.11, 95% confidence interval [CI] 1.08-1.15). Increasing utilization of NACT was observed in several sub-cohorts including patients aged <65 years, ≥65 years, White, non-White, endometrioid, non-endometrioid, and cases with non-distant organ metastasis (P < 0.05). In a multivariable analysis, NACT followed by surgery and primary surgery followed by chemotherapy had comparable OS (median 25 versus 26 months, adjusted-hazard ratio [HR] 1.03, 95%CI 0.93-1.15). When examined for metastatic extent, NACT followed by surgery was associated with decreased OS compared to primary surgery followed by chemotherapy in the non-distant organ metastasis group (adjusted-HR 1.20, 95%CI 1.05-1.36) whereas it was associated with improved OS in the distant organ metastasis group (adjusted-HR 0.79, 95%CI 0.66-0.95). CONCLUSION: The treatment of stage IVB endometrial cancer is shifting from primary surgery to NACT in the United States.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Jooya ND, Ciccone MA, Brunette LL, et al. Population-level uptake of neoadjuvant chemotherapy for stage IVB endometrial cancer. Gynecol Oncol. 2022. PMID: 35459549. doi:10.1016/j.ygyno.2022.03.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。